Corvus Pharmaceuticals (CRVS) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$2.9 million.
- Corvus Pharmaceuticals' Enterprise Value rose 3873.93% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year increase of 3873.93%. This contributed to the annual value of -$8.7 million for FY2024, which is 3074.48% up from last year.
- Corvus Pharmaceuticals' Enterprise Value amounted to -$2.9 million in Q3 2025, which was up 3873.93% from -$14.7 million recorded in Q2 2025.
- Corvus Pharmaceuticals' 5-year Enterprise Value high stood at -$2.9 million for Q3 2025, and its period low was -$31.5 million during Q1 2022.
- Moreover, its 4-year median value for Enterprise Value was -$12.6 million (2023), whereas its average is -$13.7 million.
- Data for Corvus Pharmaceuticals' Enterprise Value shows a peak YoY increase of 7672.22% (in 2024) and a maximum YoY decrease of 9379.73% (in 2024) over the last 5 years.
- Over the past 4 years, Corvus Pharmaceuticals' Enterprise Value (Quarter) stood at -$13.2 million in 2022, then rose by 4.1% to -$12.6 million in 2023, then skyrocketed by 30.74% to -$8.7 million in 2024, then soared by 67.2% to -$2.9 million in 2025.
- Its last three reported values are -$2.9 million in Q3 2025, -$14.7 million for Q2 2025, and -$5.0 million during Q1 2025.